$2.3B Houston manufacturing campus investment lifts Bristol-Myers Squibb stock

Traders Union
All News
Business & Wealth
Companies
Bristol-Myers Squibb edges higher today

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

10.08.2026

$2.3B Houston manufacturing campus investment lifts Bristol-Myers Squibb stock — Bristol-Myers Squibb edges higher today

Bristol-Myers Squibb announced a $2.3 billion plan to build a new manufacturing campus in Houston, Texas. Shares edge higher on the day, trading at $64.72.

BMY price prediction

24H 0.1%

$62.2

48H 0.42%

$62.4

7D -0.58%

$61.78

1M 6.82%

$66.38

3M 24.07%

$77.1

6M 43.26%

$89.02

12M 42.63%

$88.63

Current price: $62.14 -0.9900 1.57%

Closed 11/06

Daily range 61.59

63.04

Weekly range 61.57

65.48

Loading...

Highlights

Bristol-Myers Squibb will invest $2.3 billion to build a new manufacturing campus in Houston, supporting long-term capacity expansion.
Shares of Bristol-Myers Squibb edged higher to $64.72 following the major investment announcement.
Technical structure remains bullish, with near-term upside likely as long as the stock holds above $63.2 and trades within the expected $62.52 to $66.91 range.

Bristol-Myers Squibb announced a $2.3 billion investment to build a new manufacturing campus in Houston, Texas.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Advance grows stretched as RSI nears overbought with trend intact

RSI at 63.2 is approaching overbought territory, which points to the advance in Bristol-Myers Squibb stock becoming stretched. Price action continues to respect key technical levels, holding above the MA-20, MA-50, and MA-200, which keeps the daily structure bullish. The nearest support is the weekly low at $63.2, anchoring the chart's lower boundary within a sustained move lower that has nonetheless maintained trend firmness.

Further upside likely as traders await breakout or breakdown trigger

Traders should monitor whether price closes above $68.1 or slips below $63.2 to gauge the market's commitment to the recent action. With RSI at 63.2 nearing overbought territory, upside from here may be limited as the advance gets stretched. Even so, for the coming trading week, the probability of further upside stands at more than 80%, while the downside probability is less than 20%, with an expected range between $62.52 and $66.91. A close above $68.1 would show buyers are willing to follow through, while a drop below $63.2 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Earlier, analysts noted that Bristol-Myers Squibb was experiencing continued downside pressure with a cautious technical outlook. The latest breakout above key moving averages, supported by positive momentum after the Houston investment announcement, signals a shift to a more constructive trend, making the $68.10 resistance a critical level to monitor for confirmation of further upside.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Bristol Myers Squibb

Editor's Picks for You

From affair to market crash: How the Nvidia scandal hit Bitcoin

By Anastasiia Chabaniuk
2 hours ago

From affair to market crash: How the Nvidia scandal hit Bitcoin

Editors' Picks

Shield AI’s Echodyne deal and the global counter-drone race

By Dmytro Kharkov
3 hours ago

Shield AI’s Echodyne deal and the global counter-drone race

Editors' Picks

From airline tickets to Ferraris: What can you buy with crypto?

By Pavlo Kot
Yesterday

From airline tickets to Ferraris: What can you buy with crypto?

Editors' Picks

All Editors' Top Picks

Latest Bristol Myers Squibb News

Bristol-Myers Squibb Company shares positive 56-week trial results: Can BMY recover above the MA-50?

By Oleg Tkachenko
07.11.2026

Bristol-Myers Squibb Company shares positive 56-week trial results: Can BMY recover above the MA-50?

Companies

#Bristol Myers Squibb

Bristol-Myers Squibb announces Phase 3 trial results after stock ends session down 2.4%

By Mykhailo Ihnatenko
26.10.2026

Bristol-Myers Squibb announces Phase 3 trial results after stock ends session down 2.4%

Companies

#Bristol Myers Squibb

Bristol-Myers Squibb announces positive Phase 2 results: Will BMY hold the MA-20?

By Anton Kharitonov
08.09.2026

Bristol-Myers Squibb announces positive Phase 2 results: Will BMY hold the MA-20?

Companies

#Bristol Myers Squibb

All Bristol Myers Squibb News

Anastasiia Chabaniuk
2 hours ago

From affair to market crash: How the Nvidia scandal hit Bitcoin

Dmytro Kharkov
3 hours ago

Shield AI’s Echodyne deal and the global counter-drone race

Pavlo Kot
Yesterday

From airline tickets to Ferraris: What can you buy with crypto?

Pavlo Kot
07.11.2026

Apartment or Bitcoin: Choosing a safe haven for your wealth

Dmytro Kharkov
06.11.2026

CVS Health’s $117B split: Defensive spin-off or end of healthcare vertical integration?

Igor Krasulya
6 min ago

Lance Roberts: Questions whether market selloff signals further losses or is a temporary shakeout

Yaroslav Dmytrenko
6 min ago

Sonali Basak: U.S. 10-year Treasury at 4.85% aligns with solid growth

Mykhailo Ihnatenko
11 min ago

Cubic Analytics valuation set to increase to $24.7 million tomorrow, Caleb Franzen states

Alena Volkova
26 min ago

Jamie Coutts: Ethereum and Layer-2s market share of app fees fell as more chains gained real app economies

Yaroslav Dmytrenko
41 min ago

New behavioral finance book released, Behavioral Finance states

Top News

Oleg Tkachenko
1 hour ago

U.S. authorities grant Coinbase a banking charter

U.S. authorities grant Coinbase a banking charter

Olga Shendetskaya
1 hour ago

Oil prices fall after Trump's comments on Iran

Oil prices fall after Trump's comments on Iran

Pavlo Kot
3 hours ago

Binance, Tether and Trump-linked crypto firms face congressional scrutiny

Binance, Tether and Trump-linked crypto firms face congressional scrutiny

Dmytro Kharkov
3 hours ago

Shield AI’s Echodyne deal and the global counter-drone race

Shield AI’s Echodyne deal and the global counter-drone race

Eugene Komchuk
4 hours ago

Nvidia shares tumble amid espionage scandal involving CEO

Nvidia shares tumble amid espionage scandal involving CEO

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

EUR/USD targets 1.1200 as dollar weakens ahead of U.S. inflation data

Mykhailo Ihnatenko
Now

Ethereum slides as geopolitical risks trigger another $1B liquidation wave

Pavlo Kot
Now

Binance hackers still hold $3.1 billion in cryptocurrency after attack

Mykhailo Ihnatenko
Now

AMD stock attempts recovery after sharp sell-off wipes out post-earnings gains

Anton Kharitonov
Now

EUR/USD slips toward 1.1170 as dollar demand rises ahead of NFP

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.